Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Gregory Russotti Sells 5,000 Shares of Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 5,000 shares of the company’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $2.84, for a total value of $14,200.00. Following the sale, the insider now owns 277,319 shares in the company, valued at approximately $787,585.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Gregory Russotti also recently made the following trade(s):

• On Wednesday, June 5th, Gregory Russotti sold 5,000 shares of Century Therapeutics stock. The shares were sold at an average price of $3.00, for a total value of $15,000.00.
• On Monday, May 6th, Gregory Russotti sold 5,000 shares of Century Therapeutics stock. The shares were sold at an average price of $3.12, for a total value of $15,600.00.
• On Monday, April 22nd, Gregory Russotti sold 5,000 shares of Century Therapeutics stock. The shares were sold at an average price of $3.10, for a total value of $15,500.00.

Century Therapeutics Stock Down 6.3 %

Century Therapeutics stock opened at $2.68 on Tuesday. Century Therapeutics, Inc. has a 12 month low of $1.28 and a 12 month high of $5.51. The stock’s 50 day moving average is $3.06 and its 200-day moving average is $3.60.

Century Therapeutics (NASDAQ:IPSC) last posted its earnings results on Thursday, May 9th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.05. The company had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.30 million. Century Therapeutics had a negative return on equity of 59.74% and a negative net margin of 9,742.41%. Research analysts predict that Century Therapeutics, Inc. will post -1.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IPSC. Piper Sandler upped their price objective on Century Therapeutics from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Monday, June 17th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Century Therapeutics in a research note on Tuesday, June 4th. Finally, Canaccord Genuity Group upped their price objective on Century Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, March 15th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Century Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $13.80.

Institutional Investors Weigh In On Century Therapeutics

A number of large investors have recently added to or reduced their stakes in IPSC. Abel Hall LLC acquired a new stake in Century Therapeutics during the fourth quarter worth approximately $33,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Century Therapeutics during the first quarter worth approximately $47,000. Jacobs Levy Equity Management Inc. grew its position in Century Therapeutics by 191.0% during the first quarter. Jacobs Levy Equity Management Inc. now owns 293,941 shares of the company’s stock worth $1,229,000 after buying an additional 192,915 shares in the last quarter. Federated Hermes Inc. grew its position in Century Therapeutics by 0.4% during the fourth quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock worth $2,053,000 after buying an additional 2,500 shares in the last quarter. Finally, Avidity Partners Management LP grew its position in Century Therapeutics by 23.4% during the fourth quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock worth $4,499,000 after buying an additional 256,500 shares in the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.